Secreted phospholipase A2, lipoprotein hydrolysis, and atherosclerosis: Integration with lipidomics

Analytical and Bioanalytical Chemistry

Volumn 400, Issue 7, 2011, Pages 1829-1842

  Yamamoto, Kei ^a   Isogai, Yuki ^a   Sato, Hiroyasu ^a   Taketomi, Yoshitaka ^a   Murakami, Makoto ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Enzymes; Lipids; Mass spectrometry

Indexed keywords

ARACHIDONIC ACIDS; CELLULAR MEMBRANES; FOAM CELLS; GLYCEROPHOSPHOLIPIDS; LIPIDOMICS; LIPOPROTEIN PARTICLES; LOW DENSITY LIPOPROTEINS; LYSOPHOSPHOLIPIDS; OVER-EXPRESSION; PHARMACOLOGICAL INHIBITION; PHOSPHOLIPASE A; TRANSGENICS;

CATALYSTS; CELL MEMBRANES; CELLULAR MANUFACTURING; ENZYMES; FATTY ACIDS; HYDROLYSIS; MASS SPECTROMETRY; PHOSPHOLIPIDS; PLANTS (BOTANY);

DISEASES;

MUS;

LIPID; LIPOPROTEIN; SECRETORY PHOSPHOLIPASE A2;

ANIMAL; ATHEROSCLEROSIS; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HYDROLYSIS; METABOLISM; MOUSE; REVIEW;

ANIMALS; ATHEROSCLEROSIS; HUMANS; HYDROLYSIS; LIPIDS; LIPOPROTEINS; MICE; PHOSPHOLIPASES A2, SECRETORY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 79956261972     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-011-4864-z     Document Type: Review

References (76)

1. 2 enzymes: lessons from transgenic and knockout mice Biochimie 92 561 582 10.1016/j.biochi.2010.03.015 1:CAS:528:DC%2BC3cXmslGhtL4%3D
2. 2 Annu Rev Biochem 77 495 520 10.1146/annurev. biochem.76.062405.154007 1:CAS:528:DC%2BD1cXos1ekurk%3D
3. D Steinberg S Parthasarathy TE Carew JC Khoo JL Witztum 1989 Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity N Engl J Med 320 915 924 10.1056/NEJM198901053200122 1:CAS:528:DyaL1MXit12hur0%3D (Pubitemid 19101597)
4. MT Quinn S Parthasarathy D Steinberg 1988 Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis Proc Natl Acad Sci USA 85 2805 2809 10.1073/pnas.85.8.2805 1:CAS:528: DyaL1cXitF2kurg%3D
5. 2 enzymes in atherogenesis Curr Opin Lipidol 16 341 344 10.1097/01.mol.0000169355.20395.55 1:CAS:528:DC%2BD2MXkt1ahsbY%3D
6. 2 isozymes with a potential role in atherosclerosis Curr Opin Lipidol 14 431 436 10.1097/00041433-200310000-00003 1:CAS:528:DC%2BD3sXntlyrt7g%3D (Pubitemid 37297297)
7. 2 predict coronary events in patients with coronary artery disease Circulation 100 1280 1284 1:CAS:528:DyaK1MXmsFynsb4%3D (Pubitemid 29440119)
8. 2 activity predicts recurrent events in patients with severe acute coronary syndromes J Am Coll Cardiol 46 1249 1257 10.1016/j.jacc.2005.06.056 1:CAS:528:DC%2BD2MXhtlarsr7F (Pubitemid 41615545)
9. 2 in vascular disease Circ Res 89 298 304 10.1161/hh1601.095598 1:CAS:528:DC%2BD3MXmsVertrc%3D (Pubitemid 34132667)
10. G Schmitz K Ruebsaamen 2010 Metabolism and atherogenic disease association of lysophosphatidylcholine Atherosclerosis 208 10 18 10.1016/j.atherosclerosis.2009.05.029 1:CAS:528:DC%2BC3cXkt1eruw%3D%3D
11. N Kume MI Cybulsky MA Gimbrone Jr 1992 Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells J Clin Invest 90 1138 1144 10.1172/JCI115932 1:CAS:528:DyaK38XmtFSjsLo%3D
12. G Murugesan MR Sandhya Rani CE Gerber C Mukhopadhyay RM Ransohoff GM Chisolm K Kottke-Marchant 2003 Lysophosphatidylcholine regulates human microvascular endothelial cell expression of chemokines J Mol Cell Cardiol 35 1375 1384 10.1016/j.yjmcc.2003.08.004 1:CAS:528:DC%2BD3sXosVynsb4%3D (Pubitemid 37336565)
13. C Zhang DL Baker S Yasuda N Makarova L Balazs LR Johnson GK Marathe TM McIntyre Y Xu GD Prestwich HS Byun R Bittman G Tigyi 2004 Lysophosphatidic acid induces neointima formation through PPARγ activation J Exp Med 199 763 774 10.1084/jem.20031619 1:CAS:528:DC%2BD2cXisVagur0%3D (Pubitemid 38375196)
14. E Rother R Brandl DL Baker P Goyal H Gebhard G Tigyi W Siess 2003 Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques Circulation 108 741 747 10.1161/01.CIR.0000083715.37658.C4 1:CAS:528: DC%2BD3sXmtVWitr8%3D (Pubitemid 36999261)
15. 2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice J Clin Invest 114 784 794 1:CAS:528:DC%2BD2cXnslWiuro%3D (Pubitemid 39578737)
16. M Wang AM Zukas Y Hui E Ricciotti E Puré GA FitzGerald 2006 Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis Proc Natl Acad Sci USA 103 14507 14512 10.1073/pnas.0606586103 1:CAS:528:DC%2BD28XhtVOgtrzE (Pubitemid 44484780)
17. 2 synthase knock-out mice J Biol Chem 280 29946 29955 10.1074/jbc.M502927200 1:CAS:528:DC%2BD2MXns1SltLo%3D (Pubitemid 41177073)
18. M Mehrabian H Allayee J Wong W Shi XP Wang Z Shaposhnik CD Funk AJ Lusis 2002 Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice Circ Res 91 120 126 10.1161/01.RES. 0000028008.99774.7F 1:CAS:528:DC%2BD38XlvVCgs7Y%3D (Pubitemid 34827222)
19. T Cyrus JL Witztum DJ Rader R Tangirala S Fazio MF Linton CD Funk 1999 Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice J Clin Invest 103 1597 1604 10.1172/JCI5897 1:CAS:528:DyaK1MXjvVSntbs%3D
20. P Libby 2002 Inflammation in atherosclerosis Nature 420 868 874 10.1038/nature01323 1:CAS:528:DC%2BD38XpsFygtb8%3D (Pubitemid 36019640)
21. 2s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions Biochim Biophys Acta 1642 129 138 10.1016/S0167-4889(03)00120-4 1:CAS:528: DC%2BD3sXot1yqsbk%3D (Pubitemid 37315656)
22. 2 in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin Biochemistry 41 4911 4920 10.1021/bi015757x 1:CAS:528: DC%2BD38XitFajtbY%3D (Pubitemid 34298658)
23. 2 Biochim Biophys Acta 1736 38 50 1:CAS:528:DC%2BD2MXpslCntLY%3D (Pubitemid 41208258)
24. 2 Biochim Biophys Acta 1771 5 19 1:CAS:528:DC%2BD2sXls1ylsg%3D%3D (Pubitemid 46073888)
25. 2: preferential hydrolysis of acute phase HDL J Lipid Res 39 2150 2160 1:CAS:528:DyaK1cXnsFems7g%3D (Pubitemid 28523121)
26. Wootton PT, Arora NL, Drenos F, Thompson SR, Cooper JA, Stephens JW, Hurel SJ, Hurt-Camejo E, Wiklund O, Humphries SE, Talmud PJ (2007) Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study. Hum Mol Genet 16:1437-1444 (Pubitemid 47061339)
27. 2 group V of lipoproteins in diabetic dyslipidaemia J Intern Med 264 155 165 10.1111/j.1365-2796.2008.01932.x 1:CAS:528:DC%2BD1cXhtVCks7zO (Pubitemid 351962571)
28. 2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis J Biol Chem 283 33483 33497 10.1074/jbc.M804628200 1:CAS:528:DC%2BD1cXhsVSgt73E
29. 2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins Arterioscler Thromb Vasc Biol 17 300 309 1:CAS:528:DyaK2sXhvFCjsr0%3D (Pubitemid 27098188)
30. 2 Atherosclerosis 132 165 176 10.1016/S0021-9150(97)00088-9 1:CAS:528:DyaK2sXkvFOjt7g%3D (Pubitemid 27311008)
31. MS Brown JL Goldstein 1983 Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis Annu Rev Biochem 52 223 261 10.1146/annurev.bi.52.070183.001255 1:CAS:528:DyaL3sXltVaqur8%3D (Pubitemid 13030685)
32. R Ross 1993 The pathogenesis of atherosclerosis: a perspective for the 1990 s Nature 362 801 809 10.1038/362801a0 1:CAS:528:DyaK3sXktVGqu7c%3D (Pubitemid 23132154)
33. D Shiffman T Mikita JT Tai DP Wade JG Porter JJ Seilhamer R Somogyi S Liang RM Lawn 2000 Large scale gene expression analysis of cholesterol-loaded macrophages J Biol Chem 275 37324 37332 10.1074/jbc.M004732200 1:CAS:528:DC%2BD3cXoslWgsrY%3D (Pubitemid 32004834)
34. SD Cushing JA Berliner AJ Valente MC Territo M Navab F Parhami R Gerrity CJ Schwartz AM Fogelman 1990 Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells Proc Natl Acad Sci USA 87 5134 5138 10.1073/pnas.87.13.5134 1:CAS:528:DyaK3cXkvFGmtLg%3D (Pubitemid 20224287)
35. H Yoshida O Quehenberger N Kondratenko S Green D Steinberg 1998 Minimally oxidized low-density lipoprotein increases expression of scavenger receptor A, CD36, and macrosialin in resident mouse peritoneal macrophages Arterioscler Thromb Vasc Biol 18 794 802 1:CAS:528:DyaK1cXjsF2rsLc%3D (Pubitemid 28267660)
36. 2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation Arterioscler Thromb Vasc Biol 24 762 767 10.1161/01.ATV.0000122363.02961.c1 1:CAS:528:DC%2BD2cXisVGmt74%3D (Pubitemid 38451617)
37. 2 is linked to macrophage foam cell formation J Biol Chem 277 29116 29124 10.1074/jbc.M202867200 1:CAS:528:DC%2BD38XmsVKjsLo%3D
38. 2 induces particle fusion and enhances the retention of LDL to human aortic proteoglycans Arterioscler Thromb Vasc Biol 21 1053 1058 1:CAS:528:DC%2BD3MXksVaqu7s%3D (Pubitemid 34168668)
39. 2 type II to proteoglycans. Differential effect of glycosaminoglycans on enzyme activity J Biol Chem 271 26307 26314 10.1074/jbc.271.42.26307 1:CAS:528:DyaK28XmsVCmtrk%3D (Pubitemid 26347482)
40. 2 and decorin in human atherosclerotic lesions Circ Res 86 707 714 1:CAS:528:DC%2BD3cXitlajtrg%3D (Pubitemid 30208440)
41. 2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans J Biol Chem 280 32746 32752 10.1074/jbc.M502067200 1:CAS:528:DC%2BD2MXhtVWiurzM (Pubitemid 41368320)
42. B Sun BB Boyanovsky MA Connelly P Shridas DR van der Westhuyzen NR Webb 2007 Distinct mechanisms for OxLDL uptake and cellular trafficking by class B scavenger receptors CD36 and SR-BI J Lipid Res 48 2560 25670 10.1194/jlr.M700163-JLR200 1:CAS:528:DC%2BD2sXhsValtL7F (Pubitemid 350272840)
43. 2 hydrolysis of LDL activate macrophages to secrete pro-inflammatory cytokines Cytokine 50 50 57 10.1016/j.cyto.2009.12.009 1:CAS:528:DC%2BC3cXis1Shu70%3D
44. 2s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions. Biochim Biophys Acta 1642:129-138 (Pubitemid 37315656)
45. 2 inhibitor indoxam suppresses LDL modification and TNFα-stimulated human endothelial cells. Br J Pharmacol 153:1399-1408 (Pubitemid 351481516)
46. 2 on human endothelial cell function FASEB J 20 2547 2549 10.1096/fj.06-6018fje 1:CAS:528:DC%2BD28Xht1yntr3M (Pubitemid 44953776)
47. 2 in immune complex-mediated arthritis EMBO Mol Med 2 172 187 10.1002/emmm.201000072
48. 2 group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology. J Biol Chem 283:21640-21648
49. + regulatory T cells Proc Natl Acad Sci USA 106 11673 11678 10.1073/pnas. 0812569106
50. 2-modified low-density lipoprotein activates macrophage peroxisome proliferator-activated receptors Arterioscler Thromb Vasc Biol 30 313 320 10.1161/ATVBAHA.109.199232 1:CAS:528:DC%2BC3cXlslagtQ%3D%3D
51. 2 in atherosclerotic and nonatherosclerotic regions of human arteries Arterioscler Thromb Vasc Biol 18 519 525 1:CAS:528:DyaK1cXis1WrsLY%3D (Pubitemid 28177890)
52. 2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet Arterioscler Thromb Vasc Biol 26 1579 1585 10.1161/01.ATV.0000221231.56617.67 1:CAS:528:DC%2BD28XmvFyjurw%3D (Pubitemid 44288986)
53. 2 promotes atherosclerosis: evidence from genetically altered mice Arterioscler Thromb Vasc Biol 27 600 606 10.1161/01.ATV.0000257133.60884.44 1:CAS:528: DC%2BD2sXhsVSitbw%3D
54. 2s in human atherosclerosis development Atherosclerosis 196 81 91 10.1016/j.atherosclerosis.2006.08.062 1:CAS:528:DC%2BD1cXpt12nsQ%3D%3D
55. 2 Arterioscler Thromb Vasc Biol 19 1284 1290 1:CAS:528:DyaK1MXkvFaktb4%3D (Pubitemid 29227649)
56. Min -induced intestinal neoplasia Cell 81 957 966 10.1016/0092-8674(95)90015-2 1:CAS:528:DyaK2MXmsVagt7o%3D
57. 2 increases atherosclerotic lesion formation in LDL receptor-deficient mice Arterioscler Thromb Vasc Biol 23 263 268 10.1161/01.ATV.0000051701.90972.E5 1:CAS:528:DC%2BD3sXptFyrtw%3D%3D (Pubitemid 36231938)
58. 2 are not redundant Arterioscler Thromb Vasc Biol 26 1421 1422 10.1161/01.ATV.0000227561.89488.9a (Pubitemid 44288964)
59. -/- mouse LDL in vitro predicts its atherogenic role in vivo Arterioscler Thromb Vasc Biol 29 532 538 10.1161/ATVBAHA.108.183038 1:CAS:528:DC%2BD1MXivVektLo%3D
60. 2 augments angiotensin II-induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice Atherosclerosis 214 58 64 10.1016/j.atherosclerosis.2010.08.054
61. 2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages Arterioscler Thromb Vasc Biol 30 2014 2021 10.1161/ATVBAHA.110.210237 1:CAS:528:DC%2BC3cXhtFKlsrjL
62. 2 group X gene: relevance to coronary artery disease J Mol Med 87 723 733 10.1007/s00109-009- 0483-y 1:CAS:528:DC%2BD1MXns1ersb4%3D
63. 2 in mice leads to neonatal lethality because of lung dysfunction J Biol Chem 281 36420 36433 10.1074/jbc.M607975200 1:CAS:528:DC%2BD28Xht1ajt73N (Pubitemid 46041376)
64. 2 J Biol Chem 272 15745 15752 10.1074/jbc.272.25.15745 1:CAS:528:DyaK2sXktFCms7s%3D (Pubitemid 27265549)
65. 2 J Biol Chem 280 23203 23214 10.1074/jbc.M500985200 1:CAS:528:DC%2BD2MXltVyhu70%3D (Pubitemid 40853232)
66. 2 in reproduction, gastrointestinal phospholipid digestion, and neuronal function. J Biol Chem 286:11616-11631
67. 2 transgenic mice spontaneously develop inflammation Biochem J 421 17 27 10.1042/BJ20082429 1:CAS:528:DC%2BD1MXntFeqtLY%3D
68. 2. 2. Indole-3-acetamides with additional functionality J Med Chem 39 5119 5136 10.1021/jm960485v 1:CAS:528:DyaK28XntFejt7Y%3D (Pubitemid 27008959)
69. 2 Nat Struct Biol 2 458 465 10.1038/nsb0695-458 1:CAS:528:DyaK2MXmtFehtb8%3D
70. 2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial Lancet 373 649 658 10.1016/S0140-6736(09)60403-7 1:CAS:528:DC%2BD1MXitFyrsLc%3D
71. 2 inhibitor varespladib (A-002) J Lipid Res 50 623 629 10.1194/jlr.M800361-JLR200 1:CAS:528:DC%2BD1MXks1Wisb8%3D
72. -/- mice J Cardiovasc Pharmacol 53 60 65 10.1097/FJC.0b013e318195bfbc 1:CAS:528:DC%2BD1MXit1KnsLo%3D
73. 2 inhibitor for the potential treatment of coronary artery disease IDrugs 12 585 592 1:CAS:528:DC%2BC3cXpt1yrtrs%3D
74. 2, in the treatment of rheumatoid arthritis J Rheumatol 32 417 423 1:CAS:528:DC%2BD2MXivVyns70%3D (Pubitemid 40381410)
75. T Houjou K Yamatani H Nakanishi M Imagawa T Shimizu R Taguchi 2004 Rapid and selective identification of molecular species in phosphatidylcholine and sphingomyelin by conditional neutral loss scanning and MS3 Rapid Commun Mass Spectrum 18 3123 3130 10.1002/rcm.1737 1:CAS:528:DC%2BD2cXhtFarsbjL (Pubitemid 39664916)
76. R Taguchi T Houjou H Nakanishi T Yamazaki M Ishida M Imagawa T Shimizu 2005 Focused lipidomics by tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 823 26 36 10.1016/j.jchromb.2005.06.005 1:CAS:528:DC%2BD2MXmvVWmuro%3D (Pubitemid 41073986)